Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;20(1):2387221.
doi: 10.1080/21645515.2024.2387221. Epub 2024 Aug 14.

Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France

Paul Loubet  1 , Benjamin Gaborit  2 , Mathilde Salpin  3 , Hèlene Gardeney  4 , Ilies Benotmane  5 , Thomas Systchenko  4
Affiliations

Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France

Paul Loubet et al. Hum Vaccin Immunother. .

Abstract

France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported.

Keywords: COVID-19; immunocompromised; prophylaxis.

PubMed Disclaimer

Conflict of interest statement

Paul Loubet has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Sanofi Pasteur.

References

    1. Evans RA, Dube S, Lu Y, Yates M, Arnetorp S, Barnes E, Bell S, Carty L, Evans K, Graham S, et al. Impact of COVID-19 on immunocompromised populations during the omicron era: insights from the observational population-based INFORM study. Lancet Reg Health Eur. 2023;35:100747. doi:10.1016/j.lanepe.2023.100747. - DOI - PMC - PubMed
    1. Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, et al. Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of covid-19. N Engl J Med. 2022;386(23):2188–2. doi:10.1056/NEJMoa2116620. - DOI - PMC - PubMed
    1. Suribhatla R, Starkey T, Ionescu MC, Pagliuca A, Richter A, Lee LYW.. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients. Br J Haematol. 2023;201(5):813–823. doi:10.1111/bjh.18782. - DOI - PubMed

Substances

LinkOut - more resources